The FDA has approved Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity
The trend is larger-user-base, not smaller
GMO foods are tested multiple times by the FDA, the U.S
In the UK, NICE recommends GLP-1 receptor agonists for type 2 diabetes in specific circumstances (NG28), such as when metformin is insufficient and BMI 30 kg/m
Our investigation indicates that the pharmaceutical manufacturers of these medications, including Novo Nordisk, failed to adequately warn of these severe intestinal and stomach complications that can be caused by these drugs, causing severe and permanent injuries in many people
Since Eli Lilly financed the research and has a vested interest in the outcome, the results should be taken with caution